A member of a US Food and Drug Administration advisory committee said Wednesday he had resigned over the agency’s approval of a new Alzheimer’s drug.
A member of a US Food and Drug Administration advisory committee said Wednesday he had resigned over the agency’s approval of a new Alzheimer’s drug.